Findings: Don’t blame patients for all inhaler-use errors; singing may help improve breathing, QOL; Rx adherence does improve over time; plus 3 more outcomes of interest.
Direct Mail to Older Adults at Risk for Pneumococcal Disease Improves Vaccination Rates
A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose
Your daily dose of the clinical news you may have missed.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar
Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.
Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025
Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.